Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + TACE in Unresectable HCC
NCT01605734Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01605734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605734.